Koninklijke Philips (NYSE:PHG) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Koninklijke Philips (NYSE:PHG) from a buy rating to a hold rating in a research note released on Monday morning.

Several other brokerages have also recently commented on PHG. UBS Group raised shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday, February 20th. BNP Paribas raised shares of Koninklijke Philips from a “neutral” rating to an “outperform” rating in a report on Tuesday, February 25th. Finally, Sanford C. Bernstein raised shares of Koninklijke Philips from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 18th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Koninklijke Philips currently has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Down 2.3%

Koninklijke Philips stock opened at $23.42 on Monday. The stock has a market cap of $22.01 billion, a P/E ratio of -27.88, a P/E/G ratio of 0.82 and a beta of 0.81. The company has a quick ratio of 0.74, a current ratio of 1.23 and a debt-to-equity ratio of 0.59. Koninklijke Philips has a twelve month low of $21.48 and a twelve month high of $32.91. The company’s 50-day moving average price is $24.41 and its two-hundred day moving average price is $25.69.

Koninklijke Philips (NYSE:PHG) last announced its earnings results on Tuesday, May 6th. The technology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.14 by $0.13. Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. The company had revenue of $4.31 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the firm earned $0.21 earnings per share. The business’s revenue for the quarter was down 1.0% on a year-over-year basis. As a group, analysts expect that Koninklijke Philips will post 1.63 EPS for the current year.

Koninklijke Philips Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 13th will be given a dividend of $0.886 per share. The ex-dividend date of this dividend is Tuesday, May 13th. This represents a dividend yield of 2.9%. Koninklijke Philips’s dividend payout ratio is 174.42%.

Institutional Trading of Koninklijke Philips

Several large investors have recently made changes to their positions in PHG. Fiduciary Management Inc. WI boosted its position in shares of Koninklijke Philips by 21.7% during the 1st quarter. Fiduciary Management Inc. WI now owns 7,515,737 shares of the technology company’s stock worth $190,900,000 after acquiring an additional 1,339,055 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Koninklijke Philips by 87.7% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,222,192 shares of the technology company’s stock worth $56,266,000 after acquiring an additional 1,038,321 shares in the last quarter. Northern Trust Corp boosted its position in shares of Koninklijke Philips by 36.6% during the 4th quarter. Northern Trust Corp now owns 1,608,749 shares of the technology company’s stock worth $40,734,000 after acquiring an additional 430,757 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Koninklijke Philips during the 4th quarter worth approximately $10,655,000. Finally, GAMMA Investing LLC boosted its position in shares of Koninklijke Philips by 3,094.8% during the 1st quarter. GAMMA Investing LLC now owns 350,241 shares of the technology company’s stock worth $8,896,000 after acquiring an additional 339,278 shares in the last quarter. Institutional investors and hedge funds own 13.67% of the company’s stock.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.